Sign in

CIK 0001501697 · Non-accelerated filer<br>Smaller reporting company

X4 Pharmaceuticals, Inc

Sign in to watch
Ticker
XFOR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
273181608
Phone
857-529-8300
Business address
61 NORTH BEACON STREET, 4TH FLOOR, BOSTON, MA, 02134
Former names
Arsanis, Inc.
  1. 4 Grant or award Chief Financial Officer acquired 193,254 shares (grant or award)
  2. 3 Insider Initial Statement of Ownership
  3. 4 Grant or award Chief Legal Officer acquired 3,333 shares (grant or award)
  4. 4 Grant or award Director acquired 1,500 shares (grant or award)
  5. 4 Grant or award Director acquired 1,500 shares (grant or award)
  6. 4 Grant or award Director acquired 1,500 shares (grant or award)
  7. 4 Grant or award Director acquired 1,500 shares (grant or award)
  8. 4 Grant or award Director acquired 1,500 shares (grant or award)
  9. 4 Grant or award Director acquired 1,500 shares (grant or award)
  10. 3 Insider Initial Statement of Ownership
  11. 4/A Grant or award Chief Commercial Officer acquired 1,032 shares (grant or award)
  12. 4 Open-market buy Chief Commercial Officer bought 1,032 shares at $2.48 ($2,561)
  13. 4 Grant or award Chief Medical Officer acquired 850,000 shares (grant or award)
  14. 4 Grant or award Chief Financial Officer acquired 850,000 shares (grant or award)
  15. 4 Grant or award President and CEO acquired 2,250,000 shares (grant or award)
  16. 4 Open-market buy Chief Commercial Officer bought 35,050 shares at an average $0.55 ($19,252)
  17. 4 Grant or award Chief Operating Officer acquired 650,000 shares (grant or award)
  18. 4 Open-market sale President and CEO sold 76,473 shares at $0.45 ($34,719)
  19. 4 Open-market sale Chief Financial Officer sold 74,773 shares at $0.45 ($33,947)
  20. 4 Open-market sale Chief Commercial Officer sold 29,159 shares at $0.45 ($13,241)

Page 2 of 17 · 329 filings